Which has stronger earnings & valuation, SRRK or ARDX?

Ardelyx has higher revenue and earnings than Scholar Rock. Ardelyx is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.59 N/A Ardelyx $407.32M 3.45 -$61.60M -$0.23 N/A

Is SRRK or ARDX more profitable?

Scholar Rock has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Ardelyx -13.58% -38.11% -11.85%

Which has higher earnings and valuation, GRFS or ARDX?

Grifols has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.61 $454.82M $0.19 40.21 Ardelyx $407.32M 3.45 -$61.60M -$0.23 N/A

Is GRFS or ARDX more profitable?

Grifols has a net margin of 5.54% compared to Ardelyx's net margin of -13.58%. Grifols' return on equity of 6.21% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Grifols 5.54% 6.21% 2.39% Ardelyx -13.58% -38.11% -11.85%

Ardelyx (ARDX) Competitors

$5.69 -0.10 (-1.73%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$5.80 +0.11 (+1.93%)

As of 06/12/2026 07:15 PM Eastern

Compare

ARDX vs. APGE, SRRK, COGT, GRFS, and XENE

Should you buy Ardelyx stock or one of its competitors? MarketBeat compares Ardelyx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ardelyx include Apogee Therapeutics (APGE), Scholar Rock (SRRK), Cogent Biosciences (COGT), Grifols (GRFS), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry.

How does Ardelyx compare to Apogee Therapeutics?

Ardelyx (NASDAQ:ARDX) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Ardelyx has higher revenue and earnings than Apogee Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	3.45	-$61.60M	-$0.23	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

Apogee Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Apogee Therapeutics' return on equity of -32.64% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Apogee Therapeutics	N/A	-32.64%	-31.25%

In the previous week, Apogee Therapeutics had 9 more articles in the media than Ardelyx. MarketBeat recorded 10 mentions for Apogee Therapeutics and 1 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.89 beat Apogee Therapeutics' score of 0.80 indicating that Ardelyx is being referred to more favorably in the media.

Company	Overall Sentiment
Ardelyx	Very Positive
Apogee Therapeutics	Positive

Ardelyx has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Ardelyx presently has a consensus price target of $15.70, indicating a potential upside of 175.92%. Apogee Therapeutics has a consensus price target of $114.56, indicating a potential upside of 29.70%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts plainly believe Ardelyx is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Apogee Therapeutics	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Apogee Therapeutics beats Ardelyx on 9 of the 16 factors compared between the two stocks.

How does Ardelyx compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

In the previous week, Scholar Rock had 5 more articles in the media than Ardelyx. MarketBeat recorded 6 mentions for Scholar Rock and 1 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.89 beat Scholar Rock's score of 1.30 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Overall Sentiment
Scholar Rock	Positive
Ardelyx	Very Positive

Scholar Rock has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Ardelyx	-13.58%	-38.11%	-11.85%

Ardelyx has higher revenue and earnings than Scholar Rock. Ardelyx is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Ardelyx	$407.32M	3.45	-$61.60M	-$0.23	N/A

Scholar Rock currently has a consensus price target of $56.00, indicating a potential upside of 26.75%. Ardelyx has a consensus price target of $15.70, indicating a potential upside of 175.92%. Given Ardelyx's higher probable upside, analysts clearly believe Ardelyx is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Scholar Rock has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Scholar Rock beats Ardelyx on 9 of the 16 factors compared between the two stocks.

How does Ardelyx compare to Cogent Biosciences?

Ardelyx (NASDAQ:ARDX) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Ardelyx has higher revenue and earnings than Cogent Biosciences. Ardelyx is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	3.45	-$61.60M	-$0.23	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Ardelyx has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

In the previous week, Cogent Biosciences had 7 more articles in the media than Ardelyx. MarketBeat recorded 8 mentions for Cogent Biosciences and 1 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.89 beat Cogent Biosciences' score of 0.56 indicating that Ardelyx is being referred to more favorably in the media.

Company	Overall Sentiment
Ardelyx	Very Positive
Cogent Biosciences	Positive

Cogent Biosciences has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Cogent Biosciences	N/A	-104.27%	-54.64%

Ardelyx presently has a consensus target price of $15.70, suggesting a potential upside of 175.92%. Cogent Biosciences has a consensus target price of $43.73, suggesting a potential upside of 32.11%. Given Ardelyx's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ardelyx is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

58.9% of Ardelyx shares are held by institutional investors. 5.3% of Ardelyx shares are held by company insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Ardelyx beats Cogent Biosciences on 10 of the 16 factors compared between the two stocks.

How does Ardelyx compare to Grifols?

Grifols (NASDAQ:GRFS) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

58.9% of Ardelyx shares are held by institutional investors. 0.2% of Grifols shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Grifols and Grifols both had 1 articles in the media. Grifols' average media sentiment score of 1.89 equaled Ardelyx'saverage media sentiment score.

Company	Overall Sentiment
Grifols	Very Positive
Ardelyx	Very Positive

Grifols has a net margin of 5.54% compared to Ardelyx's net margin of -13.58%. Grifols' return on equity of 6.21% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Ardelyx	-13.58%	-38.11%	-11.85%

Grifols has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.61	$454.82M	$0.19	40.21
Ardelyx	$407.32M	3.45	-$61.60M	-$0.23	N/A

Grifols has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

Grifols currently has a consensus price target of $10.00, indicating a potential upside of 30.89%. Ardelyx has a consensus price target of $15.70, indicating a potential upside of 175.92%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Summary

Grifols beats Ardelyx on 8 of the 15 factors compared between the two stocks.

How does Ardelyx compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Xenon Pharmaceuticals presently has a consensus price target of $77.20, indicating a potential upside of 48.18%. Ardelyx has a consensus price target of $15.70, indicating a potential upside of 175.92%. Given Ardelyx's higher probable upside, analysts plainly believe Ardelyx is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Xenon Pharmaceuticals had 6 more articles in the media than Ardelyx. MarketBeat recorded 7 mentions for Xenon Pharmaceuticals and 1 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.89 beat Xenon Pharmaceuticals' score of 0.67 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Overall Sentiment
Xenon Pharmaceuticals	Positive
Ardelyx	Very Positive

Ardelyx has higher revenue and earnings than Xenon Pharmaceuticals. Ardelyx is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	671.53	-$345.91M	-$4.70	N/A
Ardelyx	$407.32M	3.45	-$61.60M	-$0.23	N/A

Xenon Pharmaceuticals has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Ardelyx	-13.58%	-38.11%	-11.85%

Xenon Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 4.1% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Xenon Pharmaceuticals beats Ardelyx on 9 of the 17 factors compared between the two stocks.

Get Ardelyx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARDX vs. The Competition

Export

Metric	Ardelyx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.41B	$3.01B	$6.76B	$12.07B
Dividend Yield	N/A	1.76%	2.67%	5.65%
P/E Ratio	-24.74	12.84	20.48	22.47
Price / Sales	3.45	302.43	511.20	109.79
Price / Cash	N/A	56.48	43.54	55.64
Price / Book	8.25	3.99	10.65	6.80
Net Income	-$61.60M	$75.85M	$3.57B	$338.00M
7 Day Performance	2.34%	1.19%	0.83%	2.68%
1 Month Performance	-10.82%	-3.23%	0.09%	2.15%
1 Year Performance	58.06%	22.55%	25.18%	30.48%

Ardelyx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARDX Ardelyx	2.8008 of 5 stars	$5.69 -1.7%	$15.70 +175.9%	+53.0%	$1.41B	$407.32M	N/A	90	Positive News
APGE Apogee Therapeutics	3.1695 of 5 stars	$83.01 -4.5%	$114.56 +38.0%	+111.0%	$5.38B	N/A	N/A	91	Insider Trade
SRRK Scholar Rock	3.5306 of 5 stars	$43.80 -1.1%	$56.00 +27.9%	+32.6%	$5.31B	N/A	N/A	140	Positive News
COGT Cogent Biosciences	2.6587 of 5 stars	$31.16 +0.5%	$43.73 +40.3%	+358.4%	$5.30B	N/A	N/A	80	News Coverage
GRFS Grifols	4.626 of 5 stars	$7.33 -4.1%	$10.00 +36.4%	-14.9%	$5.20B	$8.51B	38.58	25,247	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARDX) was last updated on 6/13/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ardelyx (ARDX) Competitors

ARDX vs. APGE, SRRK, COGT, GRFS, and XENE

How does Ardelyx compare to Apogee Therapeutics?

Summary

How does Ardelyx compare to Scholar Rock?

Summary

How does Ardelyx compare to Cogent Biosciences?

Summary

How does Ardelyx compare to Grifols?

Summary

How does Ardelyx compare to Xenon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ardelyx (ARDX) Competitors

ARDX vs. APGE, SRRK, COGT, GRFS, and XENE

How does Ardelyx compare to Apogee Therapeutics?

Which has better earnings & valuation, ARDX or APGE?

Is ARDX or APGE more profitable?

Does the media prefer ARDX or APGE?

Which has more risk & volatility, ARDX or APGE?

Do analysts prefer ARDX or APGE?

Do institutionals & insiders believe in ARDX or APGE?

Summary

How does Ardelyx compare to Scholar Rock?

Does the media favor SRRK or ARDX?

Is SRRK or ARDX more profitable?

Which has stronger earnings & valuation, SRRK or ARDX?

Do analysts recommend SRRK or ARDX?

Which has more risk & volatility, SRRK or ARDX?

Do insiders and institutionals believe in SRRK or ARDX?

Summary

How does Ardelyx compare to Cogent Biosciences?

Which has stronger earnings & valuation, ARDX or COGT?

Which has more volatility and risk, ARDX or COGT?

Does the media favor ARDX or COGT?

Is ARDX or COGT more profitable?

Do analysts rate ARDX or COGT?

Do insiders and institutionals have more ownership in ARDX or COGT?

Summary

How does Ardelyx compare to Grifols?

Do institutionals and insiders believe in GRFS or ARDX?

Does the media refer more to GRFS or ARDX?

Is GRFS or ARDX more profitable?

Which has higher earnings and valuation, GRFS or ARDX?

Which has more volatility and risk, GRFS or ARDX?

Do analysts prefer GRFS or ARDX?

Summary

How does Ardelyx compare to Xenon Pharmaceuticals?

Do analysts rate XENE or ARDX?

Does the media favor XENE or ARDX?

Which has preferable valuation & earnings, XENE or ARDX?

Is XENE or ARDX more profitable?

Which has more risk and volatility, XENE or ARDX?

Do insiders and institutionals believe in XENE or ARDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools